Prescription medication · Anticonvulsant (GABA Reuptake Inhibitor)
tiagabine
Also sold as Gabitril. Tiagabine is used to treat partial seizures in adults and children 12 years and older.
Data updated 2026-05-15
- 81
- FDA reportsRarely reported
- 11
- InteractionsSeveral interactions
- $5.41
- Generic price (NADAC)
What the data shows
tiagabine (Gabitril) is a prescription Anticonvulsant (GABA Reuptake Inhibitor), among the least-reported drugs the FDA tracks (81 FDA reports), with 11 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
tiagabine (Gabitril) is a prescription Anticonvulsant (GABA Reuptake Inhibitor). Tiagabine is used to treat partial seizures in adults and children 12 years and older.
Tiagabine is a medicine used with other medicines to treat partial seizures. It helps to control seizures by affecting certain chemicals in the brain.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$5.41/unit
Generic Available
Yes (2 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Tiagabine is used to treat partial seizures in adults and children 12 years and older.
Common side effects
Dizziness, Lack of energy, Sleepiness
Key warnings
This medicine may cause serious side effects.
The sections below are summarized in plain English from tiagabine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Tiagabine works by increasing the amount of a chemical called GABA in the brain. GABA helps to calm the brain and reduce seizures. Tiagabine blocks the reuptake of GABA, which means more GABA is available in the brain.
Side Effects (from patient reports)
Based on 81 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for tiagabine, by number of reports
- Encephalopathy
Encephalopathy
16 reports
- Myoclonus
Myoclonus
14 reports
- Dizziness 6
Dizziness
6 reports
- Feeling Abnormal 5
Feeling Abnormal
5 reports
- Seizure 5
Seizure
5 reports
- Serotonin Syndrome 4
Serotonin Syndrome
4 reports
- Toxicity To Various Agents 4
Toxicity To Various Agents
4 reports
- Tremor 4
Tremor
4 reports
- Abnormal Behaviour 3
Abnormal Behaviour
3 reports
- Completed Suicide 3
Completed Suicide
3 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for tiagabine each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where tiagabine sits
tiagabine has more FDA adverse-event reports than 1% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is tiagabine; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 81 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.
Total Reports
81
Reports Mentioning Death
7
8.6% of reports — not proof of cause
Hospitalization Reports
32
Top Indication
Multiple Sclerosis
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | ENCEPHALOPATHY | 16 |
| 2 | MYOCLONUS | 14 |
| 5 | DIZZINESS | 6 |
| 6 | FEELING ABNORMAL | 5 |
| 7 | SEIZURE | 5 |
| 9 | SEROTONIN SYNDROME | 4 |
| 10 | TOXICITY TO VARIOUS AGENTS | 4 |
| 11 | TREMOR | 4 |
| 12 | ABNORMAL BEHAVIOUR | 3 |
| 13 | COMPLETED SUICIDE | 3 |
| 14 | DRUG INTERACTION | 3 |
| 15 | DYSKINESIA | 3 |
| 16 | FATIGUE | 3 |
| 17 | HEADACHE | 3 |
| 18 | INSOMNIA | 3 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
This medicine may cause serious side effects. Tell your doctor right away if you have any changes in mood or behavior, or any suicidal thoughts.
Known Drug Interactions
Carbamazepine, phenytoin, primidone, and phenobarbital are generally classified as enzyme inducers; valproate and gabapentin are not.
Mechanism: Gabapentin does not speed up or slow down the liver enzymes that process tiagabine. This means it is unlikely to change how much tiagabine stays in your body.
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of tiagabine given as a single dose.
Mechanism: Studies show that tiagabine does not change the levels of warfarin in the blood. The two drugs do not seem to have a meaningful interaction.
Carbamazepine, phenytoin, primidone, and phenobarbital are generally classified as enzyme inducers; valproate and gabapentin are not. Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations. Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.
Mechanism: Valproate pushes tiagabine off blood proteins, which increases the amount of active tiagabine in the body. Tiagabine also slightly lowers the levels of valproate.
Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.
Mechanism: These two drugs do not interfere with each other's levels or how the body uses them.
Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.
Mechanism: Tiagabine does not change how the body breaks down or handles theophylline.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I stop taking tiagabine suddenly?
Will tiagabine interact with my other medications?
Can I drink alcohol while taking tiagabine?
How often will my dose be adjusted?
What should I do if I experience side effects?
Is it safe to drive while taking tiagabine?
Can children take tiagabine?
What do I do if I accidentally take too much tiagabine?
Does food affect how tiagabine works?
How will I know if the medicine is working?
What are the common side effects of tiagabine?
Does tiagabine interact with other medications?
What drug class is tiagabine?
What pregnancy or breastfeeding source fields are listed for tiagabine?
Related Medications in Anticonvulsant (GABA Reuptake Inhibitor)
Other drugs grouped near tiagabine - same-class peers and common alternatives.
brivaracetam
Briviact
Brivaracetam is a medicine used to treat partial-onset seizures.
Compare with tiagabine →
cannabidiol
Epidiolex
Epidiolex is a medicine that contains cannabidiol.
Compare with tiagabine →
carbamazepine
Tegretol
Carbamazepine is a medicine used to control seizures and treat nerve pain.
Compare with tiagabine →
cenobamate
Xcopri
Xcopri is a medicine used to treat partial-onset seizures in adults.
Compare with tiagabine →
clobazam
Onfi, Sympazan
Clobazam oral suspension is a medicine used with other medicines to treat seizures caused by Lennox-Gastaut syndrome.
Compare with tiagabine →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for tiagabine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 81.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 8.64%.
- artificial tears Δ 0.01 pts · 2,450 reports · Ocular Lubricant 8.65%death share
- finasteride Δ 0.03 pts · 56,567 reports · 5-Alpha Reductase Inhibitor 8.68%death share
- clarithromycin Δ 0.04 pts · 33,247 reports · Macrolide Antibiotic 8.69%death share
- primidone Δ 0.05 pts · 9,782 reports · Anticonvulsant (Barbiturate) 8.69%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on tiagabine
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for tiagabine
The FDA label for tiagabine (sold under brand names such as Gabitril) classifies it as a prescription-only medication in the Anticonvulsant (GABA Reuptake Inhibitor) class. Tiagabine is used to treat partial seizures in adults and children 12 years and older. Official labeling lists 8 commonly reported side effects, including Dizziness, Lack of energy, Sleepiness.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 81 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS shows a generic unit cost of $5.41.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: March 1, 2021
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages